Maria Laura Rubin

Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results

Renata Ferrarotto, Diana Bell, Maria Laura Rubin et al. · Clinical Cancer Research · 2020 · 127 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Marcelo V. Negrão, Vincent K. Lam, Alexandre Reuben et al. · Journal of Thoracic Oncology · 2019 · 112 citations · Full text

Life Sciences, Immunology, Oncology +17

Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients

Ho-Seok Sa, Maria Laura Rubin, Shiqiong Xu et al. · British Journal of Ophthalmology · 2018 · 85 citations · Full text

Medicine, Oncology, Surgery +17

Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma

Roberto Carmagnani Pestana, Melody Becnel, Maria Laura Rubin et al. · Oral Oncology · 2019 · 61 citations

Medicine, Immunology, Oncology +17

Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma

Bita Esmaeli, Maria Laura Rubin, Shiqiong Xu et al. · The American Journal of Surgical Pathology · 2019 · 46 citations

Medicine, Oncology, Surgery +17